Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

The user is experiencing severe hair shedding after using RU58841, stemoxydine, and minoxidil, and has stopped using finasteride due to side effects. They hope the shedding is temporary and will lead to regrowth.

The user is stressed about hair loss and is using a HIMS topical treatment containing finasteride, ketoconazole, minoxidil, and biotin, but is concerned about the oily appearance it causes. They are considering switching to Rogaine (minoxidil) due to budget constraints and side effect concerns with oral finasteride.

Clascoterone 5% solution is not yet commercially available, with only the 1% solution currently sold for acne. Users discuss the potential of Clascoterone as a hair loss treatment, comparing it to other anti-androgens like RU58841 and Eucapil.

Minoxidil causes dryness, and adding an emollient might help. The foam version is suggested to reduce dryness.

Tretinoin combined with minoxidil may improve hair regrowth, especially in difficult areas like temples, but requires diligent scalp cleaning. Some users suggest oral minoxidil as a more potent and less irritating alternative.

The conversation is about the release timeline for clinical trial results and the availability of Breezula, a hair loss treatment. The user is not comfortable buying it as a research drug from China.

The user experienced increased hair loss and scalp itchiness despite using finasteride and plans to resume minoxidil and start microneedling. They are considering using clay, Aveda thickening tonic, and a beanie to manage the appearance of thinning hair.

The conversation is about the potential aging effects of oral minoxidil on the skin. Users discuss their experiences, with some attributing skin changes to aging rather than minoxidil, and mention using tretinoin to improve skin appearance.

High-dose Lysine and Histidine supplements caused curly/kinky hair and shedding due to Elastin dysfunction. Minoxidil, white tea, and dark grape juice were mentioned as treatments to inhibit Elastase and mimic Lysyl Oxidase.

User discusses a promising topical Procyanidin B2 treatment for hair loss. Users share mixed experiences and mention effective treatments like finasteride, minoxidil, and LLLT.

The conversation is about finding a place to buy 0.025% topical finasteride in liposomal gel form in Europe. The user previously mixed their own with stemoxydine but stopped due to an oily scalp.

Pyrilutamide's effect on sebum production and scalp inflammation is unclear, with users noting no significant changes. Isotretinoin is mentioned as effective for reducing sebum, while Dutasteride and various shampoos have limited impact on oiliness and seborrheic dermatitis.

OP is experiencing significant hair loss despite GFC and PRP treatments and has abnormal lab results. They are advised to consult a hair-focused dermatologist for further evaluation.

A user experienced severe testicular pain after two weeks on oral finasteride. Another user suggested that while rare, this side effect can occur and recommended considering topical finasteride if the pain persists.

The conversation is about the use of peptide therapies for hair loss, specifically GHK-CU, ZN-Thymulin, and PTD-DBM. The user is seeking feedback on the effectiveness of these treatments from those who have tried them.

Minoxidil is causing severe scalp irritation, including itchiness and dryness, for the user. Alternatives suggested include anti-fungal treatments, propylene-glycol-free formulations, and possibly oral minoxidil.

The conversation is a humorous discussion about a Lego microneedling set for hair loss, comparing it to a wax pen. No specific treatments are mentioned.

The user experienced scalp irritation from a Finasteride and Minoxidil spray and serum. They are considering switching to foam, oral treatments, or another provider.

Kirkland Minoxidil typically contains 50-60% propylene glycol. Users suggest adjusting the percentage for sensitive skin.

The user experienced side effects from low-dose topical finasteride and is considering using clascoterone (CB-03-01) despite concerns about its risks and cost. They seek advice on its effectiveness and potential side effects compared to other treatments like alfatradiol and fluridil.

The user is experiencing severe hair shedding after taking finasteride for three weeks and plans to stop due to gynecomastia symptoms. Stopping finasteride may lead to some hair regrowth, but benefits from the treatment might be lost; topical alternatives are suggested.

The user experienced hair loss and itching after stopping RU58841 and resumed it to stop these symptoms. They also use Dutasteride and question which treatment is effective.

Using RU58841 and topical minoxidil together is fine and does not cancel out the benefits of each. Applying both treatments consecutively is acceptable.

The conversation is about Kintor's announcement indicating continued hope for their product KX-826 as a treatment for Alopecia Androgenetica. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.

The user has been using finasteride, minoxidil, a dermastamp, and red light therapy for six months with no visible improvement since the three-month mark. Other users noted improvement, particularly in the left temple area, and encouraged the user to continue.

The conversation discusses skepticism about the effectiveness and formulation of a $10 RU58841 gel from a Korean brand, questioning if ethanol is used to hold the active compounds. Concerns are raised about the feasibility of selling it at such a low price.

Man talks about hair loss in pub toilet. Users discuss avoiding mirrors and group therapy for hair loss.

Korea launched its first OTC oral hair loss drug, dexpanthenol B5. Users discuss its anti-oxidative and anti-inflammatory effects but note a lack of efficacy studies.

User started treatment with Fin and Min in 2022, added stemoxydine, and considering dut. They are unsure about microneedling due to scarring concerns.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.